Summary Keywords intermittent fasting, precision medicine, anti-obesity pharmacotherapy, cardiovascular disease, genetics, GLP-1, GIP Citation Eliopoulos AG, Gkouskou KK, Tsioufis K and Sanoudou D (2025) A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy
Drinking enough water throughout the day is essential to supporting your body's healing as well as your overall health
More than 90% of all alcoholic drinks consumed by young people involved binge drinking
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
Diabetes 56:17831791 Krauss S, Zhang CY, Scorrano L et al (2003) Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction
How many people are using GLP-1 medications By 2022, semaglutide become the dominant GLP-1 medication, accounting for 54% of use among adults with diabetes and 65% among adults without diabetes, the study noted
